Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
1996

Phase I Trial of Anti-EGFR Monoclonal Antibody ICR62 in Cancer Patients

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): H Modjtahedil, T Hickish, M Nicolson, J Moore, i Styles, S Eccles, E Jackson, J Salter, J Sloane, L Spencer, K Priest, I Smith, C Dean, M Gore

Primary Institution: Institute of Cancer Research; Royal Marsden Hospital

Hypothesis

Can the anti-EGFR monoclonal antibody ICR62 be safely administered to patients with unresectable squamous cell carcinomas?

Conclusion

MAb ICR62 can be safely administered to patients with squamous cell carcinomas and can localise efficiently to metastases.

Supporting Evidence

  • 18 patients experienced mild toxicity, but no serious side effects were observed.
  • MAb ICR62 was detected in the serum of patients treated with doses of 40 mg or more.
  • ICR62 localised to the membranes of tumour cells in biopsies taken 24 hours after treatment.

Takeaway

This study tested a new medicine on cancer patients to see if it was safe and if it could find and stick to the cancer cells.

Methodology

Patients with squamous cell carcinoma were treated with varying doses of ICR62, and their responses and antibody levels were monitored.

Limitations

The study was limited by the small sample size and the focus on safety rather than efficacy.

Participant Demographics

20 patients, 11 with head and neck cancer and 9 with lung cancer, aged 46 to 79.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication